New 'Living Drug' trial offers hope for patients with Tough-to-Treat lymphoma
NCT ID NCT06875063
Summary
This is an early-stage study testing a new type of personalized cell therapy called GB5005 in adults with a specific type of lymphoma (B-cell non-Hodgkin lymphoma) that has come back or not responded to standard treatments. The main goal is to check the safety and side effects of the treatment and see how well patients tolerate it. Researchers will also gather initial information on whether the therapy helps control the cancer and how long the modified cells last in the body.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Bing Xu
RECRUITINGXiamen, Fujian, 361000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.